According to John Hopkins University, one of the most promising new medications for weight loss is Tirzepatide, a cutting-edge medication designed to achieve medical weight loss in patients that struggle with obesity
Clinical trial data shows that tirzepatide produces injection site reactions in approximately 3-7% of patients, while semaglutide rates are generally lower at 1-2%
Tirzepatide does not place cholesterol into bile or create stones
RT exposure during transport acceptable
Patients in all 50 states can access compounded tirzepatide, and your subscription includes ongoing clinical guidance to optimize your transition and monitor your progress
Your starting point, escalation speed, and target dose depend on your individual goals, sensitivity, and provider guidance